Compare Davita Inc (DVA) vs KraneShares CSI China Internet ETF (KWEB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs KraneShares CSI China Internet ETF — how do they compare? Davita Inc trades at $178.35 (market cap $11.72B), while KraneShares CSI China Internet ETF trades at $28.09. The key difference: Davita Inc is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals.
| DVA | KWEB | |
|---|---|---|
Market Cap | $11.72B | — |
Sector | Health | Sector/Thematic |
52-Week High | $240.96 | $42.94 |
52-Week Low | $103.87 | $23.63 |
Enterprise Value | $24.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
KWEB, the KraneShares CSI China Internet ETF, trades at $28.66, up 0.99% on the day, with a bullish technical signal from moving averages and strong trend strength indicated by ADX. Recent news highlights institutional buying, China's export growth, and AI-driven factory rebounds, though RSI levels suggest potential overbought conditions. The ETF provides exposure to Chinese internet and AI companies, with performance influenced by economic policies and tech sector developments.
The outlook for KWEB is cautiously optimistic, driven by AI expansion and government support, but risks include U.S.-China tensions and regulatory shifts. Investors may find value in its tech concentration, yet must weigh geopolitical and market volatility. Analyst sentiment is mixed, balancing growth potential against structural risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →
